Experimental combo for tough melanoma shows early promise but study halted
NCT ID NCT04093323
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tested a new treatment for people with advanced melanoma that stopped responding to standard immunotherapy. The approach combined a special type of immune cell (dendritic cell therapy) with three drugs to boost the immune system and fight tumors. Only one person enrolled before the study was ended early, so we don't have enough information to know if this combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.